製藥產業的聯盟契約 (2020～2025年)

本報告提供了2020年至2025年製藥業合作協議的詳細資訊。它提供了各方宣布的合作協議的付款條款，並提供了有關付款條款和其他合約條款的寶貴見解。

主要優勢

本報告提供讀者以下主要優勢：

• 了解2020年及以後的合約趨勢
• 查看合作協議
• 基準分析：了解交易的市場價值
• 財務條款：有關預付款、里程碑付款和特許權使用費的信息
• 合約目錄：依公司（A-Z）、治療領域、技術類型分類
• 價值最高的主要合作夥伴關係列表
• 辨識最活躍的合作夥伴
• 識別每筆交易的資產和條款
• 存取合約文件：深入了解合約結構
• 盡職調查：評估您的合作條款與合作夥伴的一致性
• 節省數百小時的研究時間

調查範圍

• 生物製藥產業的聯盟契約趨勢
• 聯盟契約結構概要
• 製藥及生物科技領域的聯盟契約記錄的名錄
• 契約金額大的主要的聯盟契約
• 最活躍地進行聯盟契約的企業
• 主要的聯盟資源

可利用契約的清單:

• 企業 (A～Z)
• 契約總額
• 治療領域
• 技術類型

目錄

摘要整理

第1章 簡介

第2章 聯盟契約趨勢

• 聯盟契約定義
• 2020年以後的聯盟契約趨勢
  • 2020～2025年的聯盟契約:各年度
  • 2020～2025年的聯盟契約:各開發階段
  • 2020～2025年的聯盟契約:各業界
  • 2020～2025年的聯盟契約:各治療領域
  • 2020～2025年的聯盟契約:各技術類型
  • 2020～2025年的聯盟契約:最活躍的各企業
• 簽訂聯盟契約的理由
• 聯盟契約的未來

第3章 聯盟契約結構:概要

• 聯盟契約結構

第4章 主要聯盟契約

• 首位聯盟契約:各金額

第5章 最活躍的聯盟契約企業:前25家

• 最活躍的聯盟契約企業:前25家

第6章 含契約名錄的聯盟契約

• 包含從2020年到2025年契約的聯盟契約
• 契約名錄
• 契約名錄- 各企業聯盟契約 (A-Z)
• 契約名錄- 各治療領域的聯盟契約
• 契約名錄- 各技術類型的聯盟契約
• 關於Biopharma Research
• 目前聯盟
• 目前契約
• Current Partnering的最近報告標題

Collaboration Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter collaboration deals.

Fully revised and updated, the report provides details of collaboration deals from 2020 to 2025.

The report provides access to collaboration deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaboration contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of collaboration dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in collaboration as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of collaboration deals.

Chapter 4 provides a review of the leading collaboration deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active collaboration dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of collaboration deals organized by company A-Z, therapy, technology and industry type signed and announced since 2020 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the collaboration deal.

The deal directory includes a comprehensive listing of all collaboration deals announced since 2020. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in collaboration dealmaking since 2020.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaboration alliances.

Key benefits

Collaboration Deals in Pharmaceuticals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse collaboration deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Collaboration Deals in Pharmaceuticals is intended to provide the reader with an in-depth understanding of the collaboration trends and structure of deals entered into by leading biopharma companies worldwide.

Collaboration Deals in Pharmaceuticals includes:

• Trends in collaboration dealmaking in the biopharma industry
• Overview of collaboration deal structure
• Directory of collaboration deal records covering pharmaceutical and biotechnology
• The leading collaboration deals by value
• Most active collaboration dealmakers
• The leading collaboration partnering resources

In Collaboration Deals in Pharmaceuticals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Collaboration Deals in Pharmaceuticals provides comprehensive access to available records for collaboration deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What subcollaboration and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in collaboration dealmaking

• 2.1. Introduction
• 2.2. Definition of collaboration deal
• 2.3. Trends in collaboration deals since 2020
  • 2.3.1. Collaboration dealmaking by year, 2020-2025
  • 2.3.2. Collaboration dealmaking by phase of development, 2020-2025
  • 2.3.3. Collaboration dealmaking by industry sector, 2020-2025
  • 2.3.4. Collaboration dealmaking by therapy area, 2020-2025
  • 2.3.5. Collaboration dealmaking by technology type, 2020-2025
  • 2.3.6. Collaboration dealmaking by most active company, 2020-2025
• 2.4. Reasons for entering into collaboration partnering deals
• 2.5. The future of collaboration deals

Chapter 3 - Overview of collaboration deal structure

• 3.1. Introduction
• 3.2. Collaboration agreement structure

Chapter 4 - Leading collaboration deals

• 4.1. Introduction
• 4.2. Top collaboration deals by value

Chapter 5 - Top 25 most active collaboration dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active collaboration dealmakers

Chapter 6 - Collaboration deals including contracts directory

• 6.1. Introduction
• 6.2. Collaboration deals with contracts 2020-2025
• Deal directory
• Deal directory - collaboration dealmaking by companies A-Z
• Deal directory - collaboration dealmaking by therapy area
• Deal directory - collaboration dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of collaboration deal
• Figure 2: Trends in collaboration deal announcements, 2020-2025
• Figure 3: Collaboration deals signed at each phase of development, 2020-2025
• Figure 4: Collaboration deals by industry sector, 2020-2025
• Figure 5: Collaboration deals by therapy area, 2020-2025
• Figure 6: Collaboration deals by technology type, 2020-2025
• Figure 7: Top 25 most active collaboration dealmakers, 2020-2025
• Figure 8: Top collaboration deals by value, 2020-2025
• Figure 9: Most active collaboration dealmakers, 2020-2025